625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update

Authors :: B. Laguerre
Charles Schloss
Emanuela Romano
J.S. de Bono
Loic Mourey
Ping Qiu
Audrey E. Kam
Peter C.C. Fong
N.D. Shore
Howard Gurney
William R. Berry
Margitta Retz
Haiyan Wu
Urban Emmenegger
Tilman Todenhöfer
Leonard Joseph Appleman
G. Gravis
Henry Jacob Conter
Evan Y. Yu
Josep M. Piulats
Source :: Annals of Oncology. 31:S516-S517
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Abiraterone acetate
Hematology
Pembrolizumab
Castration resistant
medicine.disease
chemistry.chemical_compound
Prostate cancer
chemistry
Internal medicine
Cohort
medicine
Enzalutamide
In patient
business

Full Text Access

Tools